查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990377

个人化医疗市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Personalized Medicine Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，个人化医疗市场价值将达到 4,668.4 亿美元，到 2026 年将成长至 5,127.3 亿美元，到 2032 年将达到 9,239.4 亿美元，复合年增长率为 10.24%。

主要市场统计数据
基准年 2025 4668.4亿美元
预计年份：2026年 5127.3亿美元
预测年份：2032年 9239.4亿美元
复合年增长率 (%) 10.24%

个人化医疗的创新正在重新定义患者照护，并塑造下一代标靶治疗。

近年来，个人化医疗已成为医疗创新领域的前沿，它利用基因组分析和精准诊断的洞见，为每位患者量身定制治疗方案。分子生物学的突破性进展使研究人员能够揭示疾病的遗传基础，从而为靶向特定生物标记的治疗方法铺平了道路。高通量定序和生物资讯学平台的进步加速了这项从传统、统一的治疗方法向个人化介入的转变，这些平台以前所未有的方式揭示了疾病发病机制背后的分子因素。因此，临床医生可以识别出最能从特定治疗方法中获益的患者，从而提高疗效并最大限度地减少副作用。数位健康工具的整合进一步拓展了这一潜力，实现了对患者反应的持续监测和适应性治疗方案的发展。

基因组定序和数位健康平台的快速发展正在改变全球个人化医疗的格局。

过去十年，在基因组定序、数位健康整合和人工智慧分析等技术突破的推动下，个人化医疗领域经历了变革性的变化。自从全基因组定序技术问世以来，其成本已大幅下降，从而揭示了以往难以获取的患者特异性突变谱信息，并使伴随诊断在临床实践中得以常规应用。同时，数位健康平台和穿戴式装置的普及使得生物标记的远端监测成为可能，让医疗专业人员能够近乎即时地了解治疗反应和疾病进展。此外，监管机构也推出了适应性框架，以加快标靶治疗的核准，尤其是在肿瘤和罕见疾病领域，这反映了其对以患者为中心的医疗路径的更广泛承诺。

美国预计将于 2025 年加强关税力度，这将重塑全球个人化医疗市场的供应链和成本结构。

美国近期针对2025年关税调整的政策决定，为个人化医疗的价值链带来了新的复杂性。对高品质试剂、定序设备和专用实验室耗材等关键组件征收的关税，可能会增加投入成本，并扰乱现有的筹资策略。依赖跨境供应链的企业必须应对成本波动带来的利润空间压缩和策略调整。为此，许多产业相关人员正着手实现供应商多元化、探索替代製造地，并将关键生产流程在地化，以降低关税变化带来的风险。

从产品类型、技术、应用和最终用户等方面进行多样化细分，揭示了个人化医疗领域中蕴藏的微妙机会。

对市场区隔的详细分析揭示了产品类型、技术、应用和最终用户类别之间截然不同的动态，这些因素共同构成了个人化医疗的生态系统。从产品类型来看，诊断方式包括伴随诊断、基因检测、影像学和分子诊断，每种方式在识别生物标记和对患者群体进行分层方面都发挥着至关重要的作用。另一方面，治疗方案包括细胞和基因疗法、免疫疗法、单株抗体和传统药物，反映了针对疾病潜在机制的多种治疗方法。这种二分法凸显了诊断和治疗创新之间的互补性，其中准确的疾病特征描述对于制定标靶干预策略至关重要。

美洲、欧洲、中东和非洲以及亚太地区的不同区域趋势正在以各种方式推动个人化医疗的普及。

个人化医疗的区域趋势反映了美洲、欧洲、中东和非洲以及亚太地区不同的优先事项和发展轨迹。在美洲，对研究基础设施的大力投资以及主要企业的生物製药和诊断公司的存在，正在推动基因组检测和标靶治疗的快速普及。以价值为导向的倡议和倡议，以及健全的临床实验室网路和报销管道，正在进一步加速市场扩张和新型疗法的临床应用。

领先的创新者和策略伙伴关係正在加速个人化医疗生态系统的突破和竞争优势。

个人化医疗领域的主要企业正透过对研发的策略性投资以及加速治疗方法创新的合作来脱颖而出。一些生物医学公司已与基因组学技术供应商建立独家合作关係，共同开发下一代定序技术；其他公司则投资于专有的生物资讯平台，以增强对分子数据的解读能力。这些策略倡议不仅增强了企业的内部能力，也有助于它们在竞争激烈的市场环境中建立差异化优势。

透过前瞻性策略和战术性投资，产业领导者可以利用新兴的个人化医疗趋势，克服监管障碍。

为了充分利用个人化医疗的发展势头，并应对不断变化的监管和商业环境，产业领导者应考虑以下几项前瞻性策略。首先，投资模组化和灵活的製造能力将增强企业应对供应链中断和关税导致的成本波动的能力。透过建立关键部件的本地生产基地，企业既能确保供应的连续性，又能遵守区域贸易法规。同时，促进研发、监管事务和商业部门之间的跨学科合作，将能有效地将科学发现转化为可上市的解决方案，从而最大限度地缩短患者获益的时间。

严谨的资料收集、分析和检验调查方法，为个人化医疗市场提供全面的研究途径。

为确保准确性和可靠性，本分析所依据的研究采用了严谨的多阶段方法。首先，进行了二次调查，涵盖了广泛可获得的资讯来源，例如同行评审期刊、监管出版刊物和行业白皮书，以建立对技术趋势和市场动态的基本理解。在此阶段，也查阅了专利资料库和临床实验室註册信息，以识别个人化医疗领域的关键创新和开发平臺。

整合式、个人化医疗创新和策略调整可望推动全球永续成长，并改变医疗服务模式。

随着个人化医疗从概念框架走向临床实践，精准诊断、标靶治疗和数位健康平台的整合有望彻底改变全球患者的治疗效果。技术创新、策略性产业合作和适应性监管流程的整合，为更有效率的医疗服务奠定了基础。然而，供应链波动、关税影响以及区域应用差异等挑战，仍是相关人员在寻求最大限度发挥个人化医疗潜力时需要考虑的重要因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 个人化医疗市场：依产品类型划分

  • 诊断
    • 伴随诊断
    • 基因检测
    • 影像
    • 分子诊断
  • 治疗
    • 细胞和基因治疗
    • 免疫疗法
    • 单株抗体
    • 製药

第九章：个人化医疗市场：依技术划分

  • 生物资讯学
  • 月刊健康与人工智慧
  • 基因组学和蛋白​​质组学
  • 药物基因体学

第十章：个人化医疗市场：依应用领域划分

  • 循环系统
    • 心律不整
    • 心臟衰竭
  • 内分泌学
  • 感染疾病
    • 细菌
    • 病毒性的
  • 神经病学
    • 神经退化性疾病
    • 精神病学
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤

第十一章：个人化医疗市场：依最终用户划分

  • 学术和研究机构
  • 诊断检测实验室
  • 医院和诊所

第十二章 个人化医疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：个人化医疗市场：按群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 个人化医疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国个人化医疗市场

第十六章：中国的个人化医疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AMGEN INC
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc
  • Bio-Techne Corporation
  • bluebird bio, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Exact Sciences Corporation
  • GE Healthcare Technologies, Inc
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc
  • PierianDx, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4D00F1312F65

The Personalized Medicine Market was valued at USD 466.84 billion in 2025 and is projected to grow to USD 512.73 billion in 2026, with a CAGR of 10.24%, reaching USD 923.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 466.84 billion
Estimated Year [2026] USD 512.73 billion
Forecast Year [2032] USD 923.94 billion
CAGR (%) 10.24%

Innovations in Personalized Medicine Are Redefining Patient Care and Shaping the Next Generation of Targeted Therapeutics

In recent years, personalized medicine has emerged at the forefront of healthcare innovation, harnessing genomic insights and precision diagnostics to tailor treatments to individual patient profiles. Breakthroughs in molecular biology have enabled researchers to decode the genetic underpinnings of disease, paving the way for therapies that target specific biomarkers. This shift from traditional one-size-fits-all approaches to personalized interventions has been catalyzed by advancements in high-throughput sequencing and bioinformatics platforms, which deliver unprecedented resolution into the molecular drivers of pathology. As a result, clinicians can now identify patients who will benefit most from a given therapy, thereby improving efficacy rates and minimizing adverse effects. The integration of digital health tools further amplifies this potential, allowing for continuous monitoring of patient responses and adaptive treatment regimens.

Moreover, the convergence of data analytics and artificial intelligence has accelerated decision-making processes, enabling dynamic patient stratification and real-time adjustments to therapeutic protocols. Through collaborative efforts between research institutions, technology providers, and clinical stakeholders, personalized medicine is transitioning from theoretical promise to clinical reality. This introduction lays the groundwork for a comprehensive exploration of the key drivers, challenges, and emerging trends that define the evolving landscape of individualized healthcare solutions.

Rapid Advances in Genomic Sequencing and Digital Health Platforms Are Transforming the Personalized Medicine Landscape Globally

Over the past decade, the personalized medicine landscape has undergone transformative shifts driven by technological breakthroughs in genomic sequencing, digital health integration, and AI-driven analytics. The cost of whole-genome sequencing has plummeted dramatically since its inception, unlocking previously inaccessible insights into patient-specific mutation profiles and enabling the routine application of companion diagnostics in clinical practice. At the same time, the proliferation of digital health platforms and wearable devices has facilitated remote monitoring of biomarkers, empowering healthcare providers to detect treatment responses and disease progression in near real-time. In parallel, regulatory agencies have introduced adaptive frameworks that accelerate the approval of targeted therapies, particularly in oncology and rare disease domains, reflecting a broader commitment to patient-centric care pathways.

These developments have been complemented by strategic partnerships between biopharmaceutical companies and technology firms, fostering an ecosystem that leverages cross-disciplinary expertise to address complex therapeutic challenges. Collaborative research consortia now convene to standardize genomic data protocols and validate digital health endpoints, further solidifying the infrastructure needed for scalable implementation. In this context, value-based care models are increasingly being adopted, aligning reimbursement with treatment outcomes rather than volumetric service delivery. As personalized medicine continues to mature, these converging forces of innovation, policy evolution, and collaborative synergy are reshaping the healthcare paradigm, setting the stage for unprecedented levels of precision, efficiency, and patient empowerment.

Escalating United States Tariff Policies in 2025 Are Reshaping Supply Chains and Cost Structures in Personalized Medicine Markets Worldwide

Recent policy decisions regarding tariff adjustments in the United States for the year 2025 have introduced a new layer of complexity to the personalized medicine value chain. Tariffs applied to critical components such as high-grade reagents, sequencing equipment, and specialized laboratory consumables have the potential to increase input costs and disrupt established procurement strategies. Companies reliant on cross-border supply networks must now navigate a landscape where cost variances can erode profit margins and necessitate strategic recalibrations. In response, several industry players have begun diversifying their supplier base, seeking alternative manufacturing locations and localizing key production processes to mitigate exposure to tariff volatility.

Beyond direct cost implications, the tariff regime has also influenced collaborative research agreements, as international partners reassess the economic feasibility of joint ventures and technology transfers. Institutions in North America are exploring co-development frameworks with partners in tariff-exempt regions, optimizing for intellectual property protection and tax incentives. Simultaneously, small and medium-sized enterprises face heightened barriers to entry due to increased capital requirements and the need for more robust logistical planning. Despite these challenges, proactive stakeholder engagement with policy-makers and trade associations has emerged as a critical mechanism for advocating for tariff exemptions on life-saving and research-intensive products. Overall, the evolving tariff environment underscores the importance of agile supply chain strategies and cross-sector collaboration in sustaining the momentum of personalized medicine innovation.

Diverse Segmentation Across Product Types Technologies Applications and End Users Reveals Nuanced Opportunities in Personalized Medicine

An in-depth examination of market segmentation reveals distinct dynamics across product type, technology, application, and end user categories that collectively shape the personalized medicine ecosystem. Examining product type, diagnostics modalities span companion diagnostics, genetic testing, imaging diagnostics, and molecular diagnostics, each playing a pivotal role in identifying biomarkers and stratifying patient populations. Therapeutic solutions, on the other hand, encompass cell and gene therapy, immunotherapy, monoclonal antibodies, and conventional pharmaceuticals, reflecting a broad spectrum of approaches to target underlying disease mechanisms. This bifurcation underscores the complementary nature of diagnostic and therapeutic innovation, whereby precise disease characterization informs targeted intervention strategies.

When viewed through the lens of technology platforms, bioinformatics, digital health and artificial intelligence, genomics and proteomics, as well as pharmacogenomics emerge as critical enablers. Bioinformatics tools drive data interpretation, while digital health applications and AI algorithms facilitate real-time patient monitoring and adaptive treatment algorithms. Genomics and proteomics provide the molecular framework for identifying therapeutic targets, and pharmacogenomics informs drug selection based on individual metabolic profiles. These technologies function in concert to enhance the predictive power and personalized precision of clinical decision making.

Application areas further delineate the market's complexity. Cardiology divisions focus on arrhythmia and heart failure, endocrinology leverages hormone profiling, and infectious disease strategies address both bacterial and viral challenges. Neurology initiatives target neurodegenerative disorders and psychiatric conditions, while oncology efforts span hematologic malignancies and solid tumors. Finally, end user ecosystems include academic and research institutes, diagnostic laboratories, and hospitals and clinics, each serving as a crucial node in the translational continuum from discovery science to patient care. This multifaceted segmentation framework highlights the nuanced opportunities and challenges that stakeholders must navigate to drive personalized medicine forward.

Distinct Regional Dynamics Across Americas Europe Middle East Africa and Asia Pacific Are Driving Personalized Medicine Adoption Differently

Regional trends in personalized medicine reflect divergent priorities and developmental trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong investment in research infrastructure and the presence of leading biopharmaceutical and diagnostic companies drive rapid adoption of genomic testing and targeted therapies. Policy initiatives that emphasize value-based care, alongside a robust network of clinical trial sites and reimbursement pathways, further accelerate market expansion and clinical translation of novel therapies.

In contrast, the Europe Middle East and Africa region exhibits a heterogeneous landscape. Western Europe benefits from comprehensive healthcare coverage and regulatory harmonization through centralized agencies, fostering an environment conducive to the uptake of precision diagnostics and innovative treatment modalities. Conversely, emerging markets within the Middle East and Africa are characterized by nascent healthcare infrastructures and reliance on donor-funded programs, which presents both challenges and opportunities for scalable implementation of personalized medicine solutions.

Meanwhile, the Asia-Pacific region stands out for its large patient populations and growing focus on domestic manufacturing capabilities. Governments in key markets are investing in national genomic sequencing initiatives, and collaborative networks have been established to standardize data protocols and facilitate cross-border research. Additionally, partnerships between multinational corporations and local enterprises are enabling technology transfer and capacity building, positioning the region as a critical hub for future personalized medicine developments.

Leading Innovators and Strategic Collaborations Are Accelerating Breakthroughs and Competitive Positioning in the Personalized Medicine Ecosystem

Leading organizations in the personalized medicine arena are distinguishing themselves through strategic investment in research and development, as well as through collaborative alliances that accelerate therapeutic innovation. Several biomedical firms have secured exclusive partnerships with genomic technology providers to co-develop next-generation sequencing assays, while others have invested in proprietary bioinformatics platforms that enhance molecular data interpretation. These strategic maneuvers not only bolster internal capabilities but also create differentiated positioning in a highly competitive landscape.

Moreover, cross-sector collaborations are gaining momentum, with pharmaceutical companies partnering with digital health startups to integrate real-time patient monitoring into clinical trial designs. Such alliances enable more responsive trial protocols, reduce time to actionable insights, and improve patient retention rates. At the same time, emerging biotech companies are pursuing targeted acquisitions to expand their pipeline portfolios and gain access to novel therapeutic platforms, particularly in high-growth areas like cell and gene therapy. Meanwhile, diagnostic firms are forming consortia with academic institutions and contract research organizations to validate biomarkers and regulatory endpoints, reinforcing the evidentiary foundation required for market approval. By leveraging a combination of organic research efforts and external collaborations, these industry players are positioning themselves to lead the transition toward truly personalized healthcare solutions.

Proactive Strategies and Tactical Investments Will Empower Industry Leaders to Capitalize on Emerging Personalized Medicine Trends and Overcome Regulatory Hurdles

To capitalize on the momentum of personalized medicine and navigate the evolving regulatory and commercial landscape, industry leaders should consider several proactive strategies. First, investing in modular and flexible manufacturing capabilities will enhance resilience against supply chain disruptions and tariff-induced cost fluctuations. By adopting localized production hubs for critical components, organizations can ensure continuity of supply while maintaining compliance with regional trade regulations. Concurrently, fostering cross-disciplinary collaboration between R&D, regulatory affairs, and commercial teams will streamline the translation of scientific discoveries into market-ready solutions, minimizing time to patient benefit.

Second, integrating advanced data analytics and artificial intelligence into clinical development and patient engagement workflows will unlock new efficiencies. Machine learning models can predict patient responses and optimize trial design, while digital health platforms facilitate remote monitoring and adherence tracking. These technological investments will not only improve clinical outcomes but also generate real-world evidence that supports value-based reimbursement models.

Third, expanding strategic partnerships with academic centers, specialized contract research organizations, and technology providers will enhance access to cutting-edge expertise and infrastructure. Establishing co-development agreements and consortium-based research programs can spread risk and accelerate proof-of-concept validation. Additionally, engaging with policy-makers and industry associations to advocate for tariff exemptions on essential diagnostic and therapeutic components will help mitigate cost pressures.

Finally, prioritizing patient-centric frameworks-such as incorporating patient-reported outcomes and personalized engagement strategies-will strengthen adoption and long-term market success. By aligning commercialization strategies with patient needs and payer expectations, organizations can build sustainable value propositions that endure in a rapidly shifting healthcare environment.

Rigorous Data Collection Analysis and Validation Methodologies Underpinning the Comprehensive Research Approach in Personalized Medicine Markets

The research underpinning this analysis employs a rigorous multi-stage approach to ensure accuracy and reliability. Initially, secondary research was conducted across a broad spectrum of publicly available sources, including peer-reviewed journals, regulatory agency publications, and industry white papers, to establish a foundational understanding of technological trends and market dynamics. This phase also involved the review of patent databases and clinical trial registries to identify key innovations and developmental pipelines in personalized medicine.

Following this, primary research was executed through structured interviews with subject matter experts, including clinicians, technology providers, and regulatory consultants. These interviews offered qualitative insights into evolving adoption patterns, reimbursement challenges, and strategic priorities. Cross-functional dialogues with industry executives provided additional perspective on investment drivers and partnership opportunities.

Data triangulation techniques were then applied to reconcile findings from both primary and secondary sources. Quantitative data points were validated through multiple independent channels to strengthen confidence in the insights presented. Finally, an iterative validation process was conducted, where preliminary conclusions were reviewed by an external advisory panel to ensure objectivity and relevance. This comprehensive methodology ensures that the analysis reflects the latest evidence and expert perspectives, providing a robust foundation for strategic decision-making in the personalized medicine arena.

Integrated Personalized Medicine Innovations and Strategic Adaptations Are Poised to Drive Sustainable Growth and Transform Healthcare Delivery Models Worldwide

As personalized medicine advances from conceptual frameworks to clinical reality, the integration of precision diagnostics, targeted therapeutics, and digital health platforms is poised to transform patient outcomes globally. The convergence of technological innovation, strategic industry collaborations, and adaptive regulatory pathways has laid the groundwork for more effective and efficient care delivery. However, challenges such as supply chain volatility, tariff impacts, and heterogeneous regional adoption remain critical considerations for stakeholders seeking to maximize the potential of personalized interventions.

By embracing agile manufacturing strategies, fostering co-development partnerships, and leveraging advanced data analytics, organizations can navigate these complexities and achieve competitive differentiation. Simultaneously, prioritizing patient-centric approaches and cultivating evidence generation will bolster payer confidence and facilitate broader market access. As regional ecosystems continue to mature, opportunities for localized innovation and cross-border collaboration will further accelerate progress. Ultimately, the future of healthcare lies in the ability to tailor interventions to individual patient profiles, and those entities that successfully align scientific rigor with operational agility are best positioned to lead this transformative journey.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Personalized Medicine Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Companion Diagnostics
    • 8.1.2. Genetic Testing
    • 8.1.3. Imaging Diagnostics
    • 8.1.4. Molecular Diagnostics
  • 8.2. Therapeutics
    • 8.2.1. Cell & Gene Therapy
    • 8.2.2. Immunotherapy
    • 8.2.3. Monoclonal Antibodies
    • 8.2.4. Pharmaceuticals

9. Personalized Medicine Market, by Technology

  • 9.1. Bioinformatics
  • 9.2. Digital Health & AI
  • 9.3. Genomics & Proteomics
  • 9.4. Pharmacogenomics

10. Personalized Medicine Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Arrhythmia
    • 10.1.2. Heart Failure
  • 10.2. Endocrinology
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Neurology
    • 10.4.1. Neurodegenerative
    • 10.4.2. Psychiatric
  • 10.5. Oncology
    • 10.5.1. Hematologic Malignancies
    • 10.5.2. Solid Tumors

11. Personalized Medicine Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics

12. Personalized Medicine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Personalized Medicine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Personalized Medicine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Personalized Medicine Market

16. China Personalized Medicine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. AMGEN INC
  • 17.8. BGI Genomics Co., Ltd.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Biogen Inc
  • 17.11. Bio-Techne Corporation
  • 17.12. bluebird bio, Inc.
  • 17.13. CRISPR Therapeutics AG
  • 17.14. Danaher Corporation
  • 17.15. Exact Sciences Corporation
  • 17.16. GE Healthcare Technologies, Inc
  • 17.17. Guardant Health, Inc.
  • 17.18. Illumina, Inc.
  • 17.19. Myriad Genetics, Inc.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc
  • 17.22. PierianDx, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. Roche Holding AG
  • 17.25. Siemens Healthcare GmbH
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERSONALIZED MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERSONALIZED MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIGITAL HEALTH & AI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GENOMICS & PROTEOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ARRHYTHMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY PSYCHIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA PERSONALIZED MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PERSONALIZED MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)